Prior to Atherion, Dr. Rosol served as

Chief Medical Officer and later

principal executive officer of Navidea Biopharmaceuticals, a publicly traded pharmaceutical company. Before this,

he was Associate Director in the

Clinical and Translational Imaging

Group at Novartis and Head of its Translational Imaging Group.

​

He was also Sr. Director of Business Development at Elucid Bioimaging, Inc.

and CSO of MediLumine, Inc.​

 

Dr. Rosol holds a PhD from the Boston University School of Medicine and was

a post-doctoral fellow at Harvard

Medical School and the Massachusetts General Hospital. He held several

faculty appointments at large research universities, including the Mayo Clinic

and the University of Southern

California Keck School of Medicine.

Before joining Atherion, Ms. Eves

served as Navidea Biopharmaceuticals’ Vice President, Finance and

Administration from November 2020 to March 2023. She served Navidea in

several roles of increasing

responsibility beginning in March

1992, including Accounting Clerk,

Staff Accountant, Senior Accountant, Controller and Director, Finance and Administration. In addition to directing

the financial operations of the

Company, she was responsible for

internal and external financial reporting including all SEC filings, maintaining a system of internal controls, and

managing banking and vendor relationships.

​​

Ms. Eves earned a BS/BA in Accounting from The Ohio State University and is a Certified Public Accountant.

Prior to joining Atherion, Mr. Smith was

at Navidea Biopharmaceuticals from

2012 to 2023, holding various roles

up to and including VP of Operations.

He also held FP&A leadership roles at Cardinal Health, where he completed several M&A deals in expansion of the company’s PET manufacturing and radiopharmacy footprint.   

His professional career began in Operations Management at Bunge Ltd

and General Mills Inc.

 

Mr. Smith earned a Chemical

Engineering degree and Economics

minor from The Ohio State University,

and an MBA with Financial

Management emphasis from Ashland University.

Prior to joining Atherion, Ms. Hershey

was at Navidea Biopharmaceuticals

from 2016 to 2023, in roles of

increasing responsibility, culminating

in the position of Associate Director of Clinical Research and Operations. She

has worked on trials of various phases

and in a variety of disease indications, including cancers, autoimmune

disease, neurodegenerative disease,

and diseases of fibrosis.

 

Ms. Hershey earned a BS in Neuroscience/Molecular Genetics and Master of Science in Pharmacology – Clinical Pharmacology and Clinical

Trial Design from The Ohio State

University.